Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.54%
)
US TECH 100
23,319.60
(
-0.82%
)
Dow Jones
46,429.49
(
0.66%
)
Brent Oil
101.50
(
2.75%
)
Bitcoin
69,399.30
(
-2.67%
)
News Focus
News Focus
Post# of 257288
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jmkobers post# 223857

Monday, 03/04/2019 10:35:51 AM

Monday, March 04, 2019 10:35:51 AM

Post# of 257288

Something doesn't add up...

Inefficiencies in the valuations of small biotech companies can persist for quite a while. For instance, ENTA was trading at ~$45 as recently as Nov 2017—several months after Mavyret's approval by the FDA and CHMP (#msg-136356320).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today